Iacopo Marcon, PhD

ViiV Healthcare, Italy

Disclosure(s): GSK: Stocks/Bonds (Public Company); ViiV Healthcare: employee

Poster(s):

• (P-533) CD4 T-cell, CD4/CD8 Ratio Improvement and a General Reduction in Inflammatory Biomarkers with Low-Level Viremia (LLV) up to Week 192 with Fostemsavir (FTR)-Based Regimens in Individuals with Multidrug-Resistant (MDR) HIV-1
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-534) Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed with Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals with Multidrug-Resistant (MDR) HIV-1
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT